| |
Explore how oncology developers are adapting to a highly competitive and uncertain oncology therapeutic landscape. .png)
|
|
Today’s Big NewsOct 31, 2024 |
|
Wednesday, November 13 , 2024 | 10am ET / 7am PT Join industry experts to gain insights pertinent to efficient and effective drug development. Understand and execute a risk-based critical thinking approach related to injectable drug packaging and delivery. Register now. 
|
|
| By Gabrielle Masson Last year, biotech shutdowns spiked. Thankfully, 2024’s numbers are a little lower, dropping from the 27 closures in 2023 to 22 this year. |
|
|
|
By Kevin Dunleavy Forget about the “bumpiness” analysts expected from Madrigal Pharmaceuticals’ launch of potential blockbuster Rezdiffra. In its second full quarter on the market, the fatty liver disease drug racked up sales of $62 million, which routed Wall Street's expectations and triggered a 16% surge in Madrigal's share price. |
By Zoey Becker Despite the China growth woes, Merck is still confident it can achieve its $11 billion sales goal for the HPV vaccine by 2030. |
By Darren Incorvaia As the world of neurodegenerative disease drug development continues to be roiled by controversies, one company has taken a different, noninvasive approach to treating Alzheimer’s disease. |
|
Tuesday, November 12, 2024 | 2pm ET / 11am PT Major breakthroughs have been made recently in the research and development of Alzheimer’s disease. With a stronger understanding of disease pathology, new therapeutic pathways and the launch of the first disease-modifying treatments, join us to learn more about what the future holds in Alzheimer’s disease therapeutic development. Register now. 
|
|
By Fraiser Kansteiner The FDA this week revised its shortage list to note that the .25 mg starter dose of Novo’s semaglutide-based obesity med Wegovy is now available in the U.S. The .25 mg presentation of the popular metabolic medicine was the last dose of either Wegovy or its type 2 diabetes sibling Ozempic to be listed as in shortage by the FDA. |
By Darren Incorvaia Boehringer Ingelheim has halted development of an obesity drug from Gubra that it originally pledged to advance back in 2017. |
By Conor Hale The two plasma-based, in vitro tests scan for specific proteins linked to changes in the brain to help rule out the chances of Alzheimer’s among people showing cognitive decline. |
By Gabrielle Masson Paragon Therapeutics’ spinout Jade Biosciences has entered a reverse merger with Aerovate Therapeutics that will allow Jade to start trading on the Nasdaq. |
By Gabrielle Masson Amgen is discontinuing a lung disease program after its investigational small molecule failed to hit any of the primary or secondary endpoints in a midstage study. |
By Andrea Park Patient groups typically form around specific disease areas with an aim of advocating for improved treatments and therapies for patients who fall into those categories—and they’re feeling the widespread impacts of that work. |
By Gabrielle Masson Alnylam is suspending further development of a clinical-stage RNAi therapeutic designed to treat Type 2 diabetes among participants with obesity. |
By Andrea Park A new survey shows that three Big Pharmas have stolen the hearts of patient groups representing nearly 1 million people with cardiovascular conditions. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce Medtech's Conor Hale dives into EY's 18th annual Pulse of the MedTech Industry report and chats with EY's John Babbitt about the team's findings and the pace of M&A, venture capital funding and recent IPOs. |
|
|---|
|
|
|
Thursday, November 14, 2024 | 11am ET / 8am PT Join us for a deep dive into the development and manufacturing of monoclonal antibodies. We’ll explore an industry case study, providing access to key findings, top strategies and solutions for enhancing productivity and efficiency in mAb production. Don’t miss out on important insights, register now. 
|
|
Whitepaper Unlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
Whitepaper Discover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
eBook Need the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
Whitepaper Take a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
